Literature DB >> 11988310

The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma.

Ben Davidson1, Iris Goldberg, Walter H Gotlieb, Juri Kopolovic, Gilad Ben-Baruch, Jahn M Nesland, Reuven Reich.   

Abstract

The objective of this study was to analyze the correlation between matrix metalloproteinases (MMPs) and angiogenic genes and survival in advanced-stage ovarian carcinomas. Primary and metastatic ovarian carcinomas from patients diagnosed with FIGO stage III-IV disease and followed up to 20 years were studied using mRNA in situ hybridization (ISH). Expression of MMP-2, MMP-9, membrane-type 1-MMP (MT1-MMP), the MMP inhibitor TIMP-2, vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and basic fibroblast growth factor (bFGF) was studied. MMP-2, MMP-9 and TIMP-2 mRNA was detected in both tumor and stromal cells, while MT1-MMP was largely confined to tumor cells. In univariate analysis of primary tumors, TIMP-2 and MMP-9 mRNA expression correlated with poor outcome. In metastatic lesions, mRNA expression of TIMP-2, MMP-2, and MT1-MMP correlated with poor survival. In a multivariate analysis of primary tumors, TIMP-2 expression in stromal cells (P=0.006) and MMP-9 expression in tumor cells (P=0.011) retained their predictive value. Intense expression of bFGF mRNA and weak expression of IL-8 mRNA was detected in both stromal and tumor cells in most cases, while VEGF mRNA expression was limited to a few cases. Angiogenic mRNA expression showed no correlation with disease outcome in survival analysis (P>0.05). We conclude that bFGF is the major angiogenic factor expressed in ovarian carcinoma at the mRNA level. MMP-2, MMP-9, MT1-MMP and TIMP-2 are valid markers of poor survival in advanced-stage ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11988310     DOI: 10.1016/s0303-7207(01)00709-2

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  36 in total

1.  Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.

Authors:  Shahab Uddin; Azhar R Hussain; Maqbool Ahmed; Khawar Siddiqui; Fouad Al-Dayel; Prashant Bavi; Khawla S Al-Kuraya
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.

Authors:  Feng Gao; Sergio X Vasquez; Feng Su; Svetlana Roberts; Neha Shah; Victor Grijalva; Satoshi Imaizumi; Arnab Chattopadhyay; Ekambaram Ganapathy; David Meriwether; Brad Johnston; G M Anantharamaiah; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Integr Biol (Camb)       Date:  2011-02-01       Impact factor: 2.192

3.  Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.

Authors:  Anika Agarwal; Lidija Covic; Leila M Sevigny; Nicole C Kaneider; Katherine Lazarides; Gissou Azabdaftari; Sheida Sharifi; Athan Kuliopulos
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

4.  Kisspeptin regulation of human decidual stromal cells motility via FAK-Src intracellular tyrosine kinases.

Authors:  H-M Wu; H-Y Huang; Y-K Soong; P C K Leung; H-S Wang
Journal:  Hum Reprod       Date:  2019-07-08       Impact factor: 6.918

5.  Pathological characteristics, PCNA labeling index and DNA index in prognostic evaluation of patients with moderately differentiated hepatocellular carcinoma.

Authors:  Wen-Jiao Zeng; Guo-Yuan Liu; Jie Xu; Xin-Da Zhou; Yue-E Zhang; Nong Zhang
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

6.  PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.

Authors:  Karen D Cowden Dahl; Reema Zeineldin; Laurie G Hudson
Journal:  Mol Cancer Res       Date:  2007-05-02       Impact factor: 5.852

Review 7.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

8.  Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer.

Authors:  Samir F Zohny; Salah T Fayed
Journal:  Med Oncol       Date:  2009-11-24       Impact factor: 3.064

Review 9.  EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma.

Authors:  Laurie G Hudson; Natalie M Moss; M Sharon Stack
Journal:  Future Oncol       Date:  2009-04       Impact factor: 3.404

10.  Development of an optimized activatable MMP-14 targeted SPECT imaging probe.

Authors:  Gregory A Watkins; Ella Fung Jones; M Scott Shell; Henry F VanBrocklin; Mei-Hsiu Pan; Stephen M Hanrahan; Jin Jin Feng; Jiang He; Nor Eddine Sounni; Ken A Dill; Christopher H Contag; Lisa M Coussens; Benjamin L Franc
Journal:  Bioorg Med Chem       Date:  2008-12-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.